DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / MPM Bioimpact
MPM Bioimpact
MPM BioImpact is building companies to transform patient outcomes.
venture manager, reported GAV $3,027M across 20 vehicles
Importance
59
elevated
Active deployment
55
elevated
Emerging
0
low
Completeness
81
high
Freshness
100
high
Research priority
19
moderate
Identity and regulatory footprint
- Headquarters
- Boston, MAadviserinfo.sec.gov
- Office address
- 399 BOYLSTON STREET, SUITE 1100, Boston, MA, 02116adviserinfo.sec.gov
- Business phone
- 617-425-9200adviserinfo.sec.gov
- Website
- HTTP://WWW.MPMBioImpact.COM
- SEC adviser type
- registered investment adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Apr 28, 2026
- Private funds reported
- 14 (8 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $3.5Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Regulatory AUM
- $3.6Bthe adviser's RAUM, a regulatory measure, never a fund size
- Employees
- 50
- Owners on Schedule A
- Gadicke 2012 Irrevocable Trust (Member), C; Ansbert K. Gadicke 2015 Irrevocable Trust II (Member), C; MPM Capital LLC (Member), D; MPM Founders LLC (Member), E
- business phone
- 617-425-9200adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
16 observed deals
Stated (the firm’s website)
- Sectors
- healthcare, biotech
- Stages
- series a, early
- Geography
- boston, global
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series b 100%
Stage at first entry
series b 100%
Sectors
unknown 69%Biotechnology 19%Pharmaceuticals 6%Other Health Care 6%
lead rate 0%follow-on rate 0%new logos, 12 months 14
site says seed/early; 100% of first entries on record are Series B or later
Funds and vehicles
20 reported, 15 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| UBS Oncology Impact Fund L.P. | SPV or co-invest vehicle · ADV: Other Private Fund | 2023 adv first reported | Active deployment | $721M Jun 26, 2024 | 660 | unknown | unknown |
| MPM Bioventures 2022, L.P. | Fund | 2022 name year | Active deployment | $345M Jun 26, 2024 | 40 | $351M | Jun 1, 2023 |
| Oncology Impact Fund 2, L.P. | Fund · ADV: Other Private Fund | 2020 form d first sale | Mature | $826M Jun 26, 2024 | 32 | $327M | Nov 22, 2021 |
| MPM Bioventures 2018, L.P. | Fund | 2018 name year | Harvest | $653M Jun 26, 2024 | 43 | $0 of $400M | Feb 22, 2018 |
| MPM Oncology Innovations Fund L.P. | Fund | 2018 form d first sale | Harvest | $170M Jun 26, 2024 | 36 | $98.9M of $98.9M | Feb 26, 2020 |
| MPM Bioventures 2018 (b), L.P. | Fund | 2018 name year | Harvest | $33.9M Jun 26, 2024 | 8 | $0 of $400M | Feb 23, 2018 |
| MPM Asset Management Investors Bv2018 LLC | Feeder or parallel | 2018 form d first sale | Harvest | $13.6M Jun 26, 2024 | 24 | $7.5M | Nov 9, 2018 |
| MPM Asset Management Investors Bv2014 LLC | Feeder or parallel | 2018 adv first reported | Harvest | $6.7M Jun 26, 2024 | 26 | unknown | unknown |
| MPM Asset Management Investors Bv4 LLC | Feeder or parallel | 2018 adv first reported | Harvest | $3.3M Jun 26, 2024 | 28 | unknown | unknown |
| MPM Asset Management Investors Bv5 LLC | Feeder or parallel | 2018 adv first reported | Harvest | $1.9M Jun 26, 2024 | 22 | unknown | unknown |
| MPM Bioventures 2014, L.P. | Fund | 2014 name year | Harvest | $148M Jun 26, 2024 | 61 | $347M of $347M | Jul 9, 2015 |
| MPM Bioventures 2014 (b), L.P. | Fund | 2014 name year | Harvest | $9.7M Jun 26, 2024 | 13 | unknown | unknown |
| MPM Bio 2014 Nvs Strategic Fund, L.P. | Fund | 2014 name year | Harvest | $7.2M Jun 26, 2024 | 2 | $22.5M of $22.5M | Mar 24, 2015 |
| Oncology Investors of Texas Costim, LLC | Fund | 2013 form d first sale | Harvest | $947,009 Jun 26, 2024 | 8 | $1.7M of $1.7M | Sep 5, 2013 |
| MPM Bioventures V, L.P. | Fund | 2009 form d first sale | Harvest | $20.4M Jun 26, 2024 | 29 | $69.1M | Feb 12, 2010 |
| MPM Bioventures Iv-Qp, L.P. | Feeder or parallel | unknown | Unknown | $52.5M Jun 26, 2024 | 68 | unknown | unknown |
| MPM Bio IV Nvs Strategic Fund, L.P. | Fund | unknown | Unknown | $7.3M Jun 26, 2024 | 2 | unknown | unknown |
| MPM Bio V Nvs Strategic Fund, L.P. | Fund | unknown | Unknown | $5.1M Jun 26, 2024 | 2 | unknown | unknown |
| MPM Bioventures IV Gmbh & Co. Beteiligungs Kg | Fund | unknown | Unknown | $1.6M Jun 26, 2024 | 2 | unknown | unknown |
| MPM Bioventures Gmbh & Co. Parallel - Beteiligungs Kg | Feeder or parallel | unknown | Unknown | $0 Apr 1, 2015 | 34 | unknown | unknown |
| MPM Asset Management Investors Sunstates Fund LLC | Feeder or parallel | 2018 adv first reported | Wound down | $755,704 Oct 30, 2023 | 14 | unknown | unknown |
| MPM Asset Management Investors 2005 Bviii LLC | Feeder or parallel | 2005 name year | Wound down | $173,838 Jul 6, 2018 | 32 | unknown | unknown |
| MPM Asset Management Investors 2003 Bviii LLC | Feeder or parallel | 2003 name year | Wound down | $1.4M Jul 6, 2018 | 37 | unknown | unknown |
| MPM Asset Management Investors 2002 Bviii LLC | Feeder or parallel | 2002 name year | Wound down | $7,864 Jul 6, 2018 | 36 | unknown | unknown |
| MPM Bioventures Iii-Qp, L.P. | Feeder or parallel | unknown | Wound down | $68.5M Jul 6, 2018 | 100 | unknown | unknown |
| MPM Bioventures IV Strategic Fund, L.P. | Fund | unknown | Wound down | $8.1M Mar 29, 2021 | 2 | unknown | unknown |
| MPM Bioventures III Gmbh & Co. Beteiligungs Kg | Fund | unknown | Wound down | $5.9M Jul 6, 2018 | 17 | unknown | unknown |
| MPM Bioventures Strategic Fund, L.P. | Fund | unknown | Wound down | $4.8M Jul 6, 2018 | 1 | unknown | unknown |
| MPM Bioventures III, L.P. | Fund | unknown | Wound down | $4.6M Jul 6, 2018 | 9 | unknown | unknown |
| MPM Bioventures III Parallel Fund, L.P. | Feeder or parallel | unknown | Wound down | $2.1M Jul 6, 2018 | 2 | unknown | unknown |
| MPM Sunstates Fund, L.P. | Fund | unknown | Wound down | $1.6M Oct 30, 2023 | 5 | unknown | unknown |
| MPM Bioventures Ii-Qp ,L.P. | Feeder or parallel | unknown | Wound down | $0 Apr 1, 2015 | 81 | unknown | unknown |
| BB Bioventures, L.P. | Fund | unknown | Wound down | $0 Sep 19, 2013 | 35 | unknown | unknown |
| MPM Bioventures II, L.P. | Fund | unknown | Wound down | $0 Apr 1, 2015 | 17 | unknown | unknown |
| MPM Bioventure Parallel Fund, L.P. | Feeder or parallel | unknown | Wound down | $0 Sep 19, 2013 | 5 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
27 current, 19 departed
Ansbert Gadicke
AssociateInvestment Team
Binsen Li
AssociateInvestment Team
David Kolesky
AssociateInvestment Team
Detlev Biniszkiewicz
AssociateInvestment Team
Rami Rahal
AssociateInvestment Team
Sam Goldman
AssociateInvestment Team
Ansbert S Gadicke
Board or advisoryTrustee · since Jan 1, 2012
Christiana Goh Bardon
Board or advisoryTrustee · since Nov 1, 2015
Luke Evnin
Board or advisoryAdvisor
Paul Karger
Board or advisoryTrustee · since Jan 1, 2015
Ying Huang
Board or advisoryStrategic Advisor, APAC
Intellectual Property
OtherDr. Grey Sieczkiewicz serves as IP Counsel to several MPM BioImpact portfolio companies.
Andrew M. Scharenberg
PartnerEntrepreneur Partner
Aparna Parikh
PartnerENTREPRENEUR PARTNER
Briggs Morrison
PartnerEntrepreneur Partner
Elizabeth Stoner
PartnerEntrepreneur Partner
Frank Neumann
PartnerEntrepreneur Partner
Luke Basil Evnin
PartnerMember · since Dec 1, 1999
Matthew Roden
PartnerEntrepreneur Partner
Pankaj Bhargava
PartnerEntrepreneur Partner
Todd Foley
PartnerManaging Director · since Nov 1, 2015
Brendan Furey
Platform and operationsBrendan is the Chief Compliance Officer of MPM BioImpact.
Brendan Michael Furey
Platform and operationsChief Compliance Officer · since Nov 1, 2022
Gisella de la Rocha
Platform and operationsGisella de la Rocha is Vice President of Legal at MPM BioImpact.
Kristen Lee Laguerre
Platform and operationsPartner, Finance And Operations · since Oct 1, 2019
Robert Risoleo
Platform and operationsBob Risoleo is the General Counsel at MPM BioImpact.
Robert Samuel Risoleo
Platform and operationsGeneral Counsel · since Jan 1, 2024
19 departed (kept with end dates)
- Binsen Li · Investment Team · ? to Sep 16, 2026 Inference
- David Kolesky · Investment Team · ? to Sep 16, 2026 Inference
- Detlev Biniszkiewicz · Investment Team · ? to Sep 16, 2026 Inference
- Rami Rahal · Investment Team · ? to Sep 16, 2026 Inference
- Sam Goldman · Investment Team · ? to Sep 16, 2026 Inference
- Luke Evnin · Advisor · ? to Sep 16, 2026 Inference
- Ying Huang · Strategic Advisor, APAC · ? to Sep 16, 2026 Inference
- Bard Geesaman · Managing Director · Nov 1, 2015 to Mar 28, 2019 Inference
- Edward Martin Hurwitz · Managing Director · Nov 1, 2015 to Mar 30, 2023 Inference
- James Paul Scopa · Managing Director · Nov 1, 2015 to Mar 30, 2018 Inference
- Matthew Roden · Entrepreneur Partner · ? to Sep 16, 2026 Inference
- Steven St. Peter · Managing Director · Jan 1, 2004 to Mar 18, 2013 Inference
- Vaughn Kailian · Managing Director · May 1, 2005 to Apr 1, 2015 Inference
- Howard Bruce Rubin · Chief Compliance Officer · Mar 1, 2018 to Jul 16, 2019 Inference
- Jeff William Crispen · Chief Compliance Officer · Mar 1, 2022 to Nov 17, 2022 Inference
- John W. Vander Vort · Managing Director, Chief Operating Officer & Chief Compliance Officer · May 1, 2005 to Sep 19, 2013 Inference
- Lauren Cauley · Chief Financial Officer · Nov 1, 2015 to Jul 16, 2019 Inference
- Nicholas Myles Mcgrath · General Counsel And Chief Compliance Officer · Jun 1, 2019 to Mar 23, 2022 Inference
- Sarah Reed · Chief Operating Officer And General Counsel · Nov 1, 2015 to Jul 16, 2019 Inference
Investments on record
16 edges, 16 companies, 3 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
18 relationships from shared deals, counted for the whole firm
Mitsui & Co. Global Investment, Inc. 1 shared · one timeBlackbird Ventures Pty Ltd. 1 shared · one timeArtisanal Ventures, LLC 1 shared · one timeAdjuvant Capital, LP 1 shared · one timeDCVC 1 shared · one timeSofinnova Investments, Inc. 1 shared · one timePappas Ventures 1 shared · one timeGreat Oaks Management Company LLC 1 shared · one timeYouTube 1 shared · one timeAgent Capital, LLC 1 shared · one timeFemhealth Ventures Management LLC 1 shared · one timeNovartis Venture Fund 1 shared · one time · they led 1Forbion 1 shared · one time · they led 1Vida Ventures 1 shared · one timeDroia Ventures 1 shared · one timeYK Bioventures 1 shared · one timeLightspeed Venture Partners 1 shared · one timeChris Weyrer 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
80 dated events
- Sep 16, 2026Matthew Roden (Entrepreneur Partner) no longer on the team page of MPM BioimpactPerson leftPeopleInferenceMatthew RodenVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Rami Rahal (Investment Team) no longer on the team page of MPM BioimpactPerson leftPeopleInferenceRami RahalVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Binsen Li (Investment Team) no longer on the team page of MPM BioimpactPerson leftPeopleInferenceBinsen LiVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026David Kolesky (Investment Team) no longer on the team page of MPM BioimpactPerson leftPeopleInferenceDavid KoleskyVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Ying Huang (Strategic Advisor, APAC) no longer on the team page of MPM BioimpactPerson leftPeopleInferenceYing HuangVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Sam Goldman (Investment Team) no longer on the team page of MPM BioimpactPerson leftPeopleInferenceSam GoldmanVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Luke Evnin (Advisor) no longer on the team page of MPM BioimpactPerson leftPeopleInferenceLuke EvninVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Detlev Biniszkiewicz (Investment Team) no longer on the team page of MPM BioimpactPerson leftPeopleInferenceDetlev BiniszkiewiczVenture organization websites (about, team, portfolio, thesis, news pages)
- Mar 28, 2024MPM Asset Management Investors Sunstates Fund LLC no longer reported on Form ADV by MPM Bioimpact
- Mar 28, 2024MPM Sunstates Fund, L.P. no longer reported on Form ADV by MPM BioimpactFund no longer reportedFundsInferenceMPM Sunstates Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Jan 1, 2024Robert Samuel Risoleo joined Schedule A of MPM Bioimpact as General Counsel
- Mar 30, 2023Oncology Impact Fund 2, L.P. first reported on Form ADV by MPM Asset Management LLC (Other Private Fund), GAV $828,188,146Fund first reported on Form ADVFundsFactOncology Impact Fund 2, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2023UBS Oncology Impact Fund L.P. first reported on Form ADV by MPM Asset Management LLC (Other Private Fund), GAV $785,026,985Fund first reported on Form ADVFundsFactUBS Oncology Impact Fund L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2023MPM Bioventures 2022, L.P. first reported on Form ADV by MPM Asset Management LLC (Private Equity Fund), GAV $337,703,600Fund first reported on Form ADVFundsFactMPM Bioventures 2022, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2023Edward Martin Hurwitz (Managing Director) no longer on Schedule A of MPM Asset Management LLC
- Nov 17, 2022Jeff William Crispen (Chief Compliance Officer) no longer on Schedule A of MPM Asset Management LLC
- Nov 1, 2022Brendan Michael Furey joined Schedule A of MPM Asset Management LLC as Chief Compliance Officer
- Mar 23, 2022Nicholas Myles Mcgrath (General Counsel And Chief Compliance Officer) no longer on Schedule A of MPM Asset Management LLC
- Mar 23, 2022MPM Bioventures IV Strategic Fund, L.P. no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Bioventures IV Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 1, 2022Jeff William Crispen joined Schedule A of MPM Asset Management LLC as Chief Compliance Officer
- Jul 16, 2019Lauren Cauley (Chief Financial Officer) no longer on Schedule A of MPM Asset Management LLC
- Jul 16, 2019Howard Bruce Rubin (Chief Compliance Officer) no longer on Schedule A of MPM Asset Management LLC
- Jul 16, 2019Sarah Reed (Chief Operating Officer And General Counsel) no longer on Schedule A of MPM Asset Management LLC
- Jun 1, 2019Kristen Lee Laguerre joined Schedule A of MPM Asset Management LLC as Managing Director, Finance
- Jun 1, 2019Nicholas Myles Mcgrath joined Schedule A of MPM Asset Management LLC as General Counsel And Chief Compliance Officer
- Mar 28, 2019MPM Asset Management Investors 2005 Bviii LLC no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Asset Management Investors 2005 Bviii LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2019MPM Asset Management Investors 2003 Bviii LLC no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Asset Management Investors 2003 Bviii LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2019MPM Oncology Innovations Fund L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $49,701,408Fund first reported on Form ADVFundsFactMPM Oncology Innovations Fund L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2019MPM Bioventures III, L.P. no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Bioventures III, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2019MPM Bioventures III Gmbh & Co. Beteiligungs Kg no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Bioventures III Gmbh & Co. Beteiligungs KgSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2019MPM Bioventures Iii-Qp, L.P. no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Bioventures Iii-Qp, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2019MPM Asset Management Investors 2002 Bviii LLC no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Asset Management Investors 2002 Bviii LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2019Bard James Geesaman (Managing Director) no longer on Schedule A of MPM Asset Management LLC
- Mar 28, 2019MPM Bioventures III Parallel Fund, L.P. no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Bioventures III Parallel Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2019MPM Bioventures Strategic Fund, L.P. no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Bioventures Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Asset Management Investors Bv5 LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $13,260,583Fund first reported on Form ADVFundsFactMPM Asset Management Investors Bv5 LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018James Paul Scopa (Managing Director) no longer on Schedule A of MPM Asset Management LLC
- Mar 30, 2018MPM Asset Management Investors Bv2014 LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $11,305,115Fund first reported on Form ADVFundsFactMPM Asset Management Investors Bv2014 LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Asset Management Investors Bv2018 LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund)Fund first reported on Form ADVFundsFactMPM Asset Management Investors Bv2018 LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Asset Management Investors Bv4 LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $7,797,790Fund first reported on Form ADVFundsFactMPM Asset Management Investors Bv4 LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Asset Management Investors 2005 Bviii LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $173,838Fund first reported on Form ADVFundsFactMPM Asset Management Investors 2005 Bviii LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Asset Management Investors Sunstates Fund LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $2,720,102Fund first reported on Form ADVFundsFactMPM Asset Management Investors Sunstates Fund LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Bioventures 2018 (b), L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $19,750,000Fund first reported on Form ADVFundsFactMPM Bioventures 2018 (b), L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Asset Management Investors 2003 Bviii LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $1,354,512Fund first reported on Form ADVFundsFactMPM Asset Management Investors 2003 Bviii LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Asset Management Investors 2002 Bviii LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $7,864Fund first reported on Form ADVFundsFactMPM Asset Management Investors 2002 Bviii LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2018MPM Bioventures 2018, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $284,900,000Fund first reported on Form ADVFundsFactMPM Bioventures 2018, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 1, 2018Howard Bruce Rubin joined Schedule A of MPM Asset Management LLC as Chief Compliance Officer
- Nov 1, 2015Lauren Cauley joined Schedule A of MPM Asset Management LLC as Chief Financial Officer
- Nov 1, 2015Christiana Goh Bardon joined Schedule A of MPM Asset Management LLC as Trustee
- Nov 1, 2015Sarah Reed joined Schedule A of MPM Asset Management LLC as Chief Operating Officer And General Counsel
- Nov 1, 2015Bard Geesaman joined Schedule A of MPM Asset Management LLC as Chief Compliance Officer
- Nov 1, 2015Edward Martin Hurwitz joined Schedule A of MPM Asset Management LLC as Managing Director
- Apr 1, 2015MPM Bio 2014 Nvs Strategic Fund, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $2,000,000Fund first reported on Form ADVFundsFactMPM Bio 2014 Nvs Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 1, 2015MPM Bioventures 2014 (b), L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $1,234,249Fund first reported on Form ADVFundsFactMPM Bioventures 2014 (b), L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 1, 2015MPM Bioventures 2014, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $20,236,833Fund first reported on Form ADVFundsFactMPM Bioventures 2014, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 1, 2015Vaughn Kailian (Managing Director) no longer on Schedule A of MPM Asset Management LLC
- Jan 1, 2015Paul Karger joined Schedule A of MPM Asset Management LLC as Trustee
- Apr 1, 2014Oncology Investors of Texas Costim, LLC first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $6,281,553Fund first reported on Form ADVFundsFactOncology Investors of Texas Costim, LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 1, 2014MPM Bioventure Parallel Fund, L.P. no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceMPM Bioventure Parallel Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 1, 2014BB Bioventures, L.P. no longer reported on Form ADV by MPM Asset Management LLCFund no longer reportedFundsInferenceBB Bioventures, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Sep 19, 2013John W. Vander Vort (Managing Director, Chief Operating Officer & Chief Compliance Officer) no longer on Schedule A of MPM Asset Management LLC
- Mar 18, 2013Steven St. Peter (Managing Director) no longer on Schedule A of MPM Asset Management LLC
- Mar 28, 2012MPM Bioventures III Parallel Fund, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $5,723,514Fund first reported on Form ADVFundsFactMPM Bioventures III Parallel Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bio IV Nvs Strategic Fund, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $45,493,662Fund first reported on Form ADVFundsFactMPM Bio IV Nvs Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bio V Nvs Strategic Fund first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $5,550Fund first reported on Form ADVFundsFactMPM Bio V Nvs Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures V, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $54,165,655Fund first reported on Form ADVFundsFactMPM Bioventures V, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Sunstates Fund, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund)Fund first reported on Form ADVFundsFactMPM Sunstates Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures IV Gmbh & Co. Beteiligungs Kg first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $11,963,503Fund first reported on Form ADVFundsFactMPM Bioventures IV Gmbh & Co. Beteiligungs KgSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures IV Strategic Fund, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $10,510,803Fund first reported on Form ADVFundsFactMPM Bioventures IV Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Asset Management LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures Ii-Qp ,L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $69,211,556Fund first reported on Form ADVFundsFactMPM Bioventures Ii-Qp ,L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventurs Iv-Qp, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $309,206,240Fund first reported on Form ADVFundsFactMPM Bioventures Iv-Qp, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures II, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $7,624,796Fund first reported on Form ADVFundsFactMPM Bioventures II, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventure Parallel Fund, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $2,855,631Fund first reported on Form ADVFundsFactMPM Bioventure Parallel Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures Gmbh & Co. Parallel - Beteiligungs Kg first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $24,563,965Fund first reported on Form ADVFundsFactMPM Bioventures Gmbh & Co. Parallel - Beteiligungs KgSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures III Gmbh & Co. Beteiligungs Kg first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $16,151,269Fund first reported on Form ADVFundsFactMPM Bioventures III Gmbh & Co. Beteiligungs KgSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures III, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $13,249,160Fund first reported on Form ADVFundsFactMPM Bioventures III, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures Iii-Qp, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $197,305,122Fund first reported on Form ADVFundsFactMPM Bioventures Iii-Qp, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012MPM Bioventures Strategic Fund, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $8,892,975Fund first reported on Form ADVFundsFactMPM Bioventures Strategic Fund, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2012BB Bioventures, L.P. first reported on Form ADV by MPM Asset Management LLC (Venture Capital Fund), GAV $29,168,766Fund first reported on Form ADVFundsFactBB Bioventures, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 15, 2026Institutional venture firm (probable, 80%, cls-1)venture manager, reported GAV $3,027M across 20 vehicles
- Sep 12, 2026Institutional venture firm (probable, 80%, cls-1)venture manager, reported GAV $2,962M across 17 vehicles
Evidence
71 observations from 3 sources